CTHRC1 promotes bone metastasis in prostate cancer
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70012 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yuichiro Sawada und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan. Hauptthemen laut MEDLINE: Bone Neoplasms, Prostatic Neoplasms, Extracellular Matrix Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
Prostate cancer causes a high frequency of bone metastases. The purpose of this study was to identify molecules that regulate prostate cancer bone metastasis as potential therapeutic and/or prognostic targets in prostate cancer, using integrative genome‐wide data. Based on the biological characterization of prostate cancer cell lines and integrated big data analysis of clinical samples, we identified CTHRC1 as a candidate gene that regulates prostate cancer bone metastasis. The knockdown of CTHRC1 suppressed cell migration and cell adhesion, but not cell proliferation, in vitro and in vivo. In a mouse tibia xenograft model, CTHRC1 knockdown markedly suppressed metastatic growth of prostate cancer cells in the bone microenvironment. CTHRC1 also promoted in vitro osteoclast differentiation. The analysis of 343 human prostate cancer biopsy samples showed that CTHRC1 expression was positively correlated with bone metastasis, indicating that CTHRC1 could be a useful predictive marker for bone metastasis. Our findings illustrate the clinical relevance of CTHRC1 and demonstrate that CTHRC1 plays an important role in prostate cancer bone metastasis. CTHRC1 may be useful for predicting prostate cancer bone metastasis and may lead to the development of new methods for the prevention and treatment of metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Pathophysiology, Ehime University Graduate School of Medicine, Toon, Japan.
- Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Toon, Japan.
- Division of Medical Research Support, Advanced Research Support Center, Ehime University, Toon, Japan.
- Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
- Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
ORCID-Profile: Yuichiro Sawada, Yuuki Imai
Förderung
- Takeda Science Foundation
- Japan Society for the Promotion of Science (JSPS)
Zitieren
APA
Sawada, Y., Kikugawa, T., Onishi, T., Arai, O., Iio, H., Miura, N., Yoshida, S., Ikedo, A., Yanagihara, Y., Saeki, N., Sakakibara, I., Győrffy, B., Kishida, T., Okubo, Y., Nakamura, Y., Sato, S., Miyagi, Y., Saika, T., & Imai, Y. (2025). CTHRC1 promotes bone metastasis in prostate cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70012
Vancouver
Sawada Y, Kikugawa T, Onishi T, Arai O, Iio H, Miura N, et al. CTHRC1 promotes bone metastasis in prostate cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.70012
BibTeX
@article{Sawada2025,
author = {Sawada, Yuichiro and Kikugawa, Tadahiko and Onishi, Tomoya and Arai, Osuke and Iio, Hiroyuki and Miura, Noriyoshi and Yoshida, Shuhei and Ikedo, Aoi and Yanagihara, Yuta and Saeki, Noritaka and Sakakibara, Iori and Győrffy, Balázs and Kishida, Takeshi and Okubo, Yoichiro and Nakamura, Yoshiyasu and Sato, Shinya and Miyagi, Yohei and Saika, Takashi and Imai, Yuuki},
title = {CTHRC1 promotes bone metastasis in prostate cancer},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70012}
}
EUVIMED